Cue Biopharma Inc

NASDAQ:CUEUnited States

Yesterday

Show headlines and story abstract

• *DJ Cue Biopharma 3Q Loss/Shr 17c >CUE, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CUE
  
  For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
  
  Forward-Looking Statements
  
  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's belief that the CUE-100 series represents the potential of establishing a new standard of care for cancer patients; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; the company's business strategies, plans and prospects, including the advancement of the company's preclinical autoimmune programs toward drug candidate selection ; and the cash runway of the company and the sufficiency of the company's cash and cash equivalents to fund its operations. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company's ability to shift its focus to its autoimmune assets and achieve the cost savings that it is projecting; the company's limited operating history, limited cash and a history of losses; the company's ability to achieve profitability; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ("FDA") or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the future; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
  

• Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CUE
  
  For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
  
  Forward-Looking Statements
  
  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's belief that the CUE-100 series represents the potential of establishing a new standard of care for cancer patients; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; the company's business strategies, plans and prospects, including the advancement of the company's preclinical autoimmune programs toward drug candidate selection ; and the cash runway of the company and the sufficiency of the company's cash and cash equivalents to fund its operations. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company's ability to shift its focus to its autoimmune assets and achieve the cost savings that it is projecting; the company's limited operating history, limited cash and a history of losses; the company's ability to achieve profitability; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ("FDA") or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the future; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
  

• Press Release: Cue Biopharma Announces Strategic Organizational Transition, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CUE
  
  Cue Biopharma Announces Strategic Organizational Transition
  -- Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024 -- Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor
  

• Cue Biopharma Announces Strategic Organizational Transition, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: CUE
  
  Cue Biopharma Announces Strategic Organizational Transition
  -- Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, November 25, 2024 -- Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor